Login to Your Account



Beigene discloses science behind its three phase I cancer candidates

By Shannon Ellis
Staff Writer

Wednesday, April 29, 2015
SHANGHAI – Beigene Co. Ltd. has three candidates currently in phase I trials in Australia and has revealed the science and possible indications behind the cancer compounds: BGB-283, a second generation inhibitor of B-RAF; BGB-290, a poly (ADP-ribose) polymerase (PARP) inhibitor and BGB-3111 inhibitor of Bruton tyrosine kinase (BTK).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription